Selected research
Industry Research
Anti-PD-1 Antibody Industry Research Report 2026
Market perspective
The global Anti-PD-1 Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-PD-1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-PD-1 Antibody is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-PD-1 Antibody is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-PD-1 Antibody include 3SBio Inc, Thermo Fisher, Novartis, Merck, Lilly, Sino Biological Inc, Bristol-Myers Squibb (BMS), Abcam and Abbvie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-PD-1 Antibody market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-PD-1 Antibody Market by Company
3SBio Inc
Thermo Fisher
Novartis
Merck
Lilly
Sino Biological Inc
Bristol-Myers Squibb (BMS)
Abcam
Abbvie
TG Therapeutics, Inc
Ono Pharmaceutical Co., Ltd
InvivoGen
Chugai Pharmaceutical Co., Ltd
BioVision Inc
Bio X Cell
BeiGene
Arcus Biosciences
Anti-PD-1 Antibody Segment by Type
Monoclonal
Polyclonal
Anti-PD-1 Antibody Segment by Application
IHC-P
ICC/IF
ELISA
Flow Cytometry
WB
Anti-PD-1 Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-PD-1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-PD-1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-PD-1 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-PD-1 Antibody manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-PD-1 Antibody by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-PD-1 Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal
- Polyclonal
Applications
- IHC-P
- ICC/IF
- ELISA
- Flow Cytometry
- WB
Companies covered
- 3SBio Inc
- Thermo Fisher
- Novartis
- Merck
- Lilly
- Sino Biological Inc
- Bristol-Myers Squibb (BMS)
- Abcam
- Abbvie
- TG Therapeutics, Inc
- Ono Pharmaceutical Co., Ltd
- InvivoGen
- Chugai Pharmaceutical Co., Ltd
- BioVision Inc
- Bio X Cell
- BeiGene
- Arcus Biosciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-PD-1 Antibody Market Size (2021-2032)
- 2.2.2 Global Anti-PD-1 Antibody Sales (2021-2032)
- 2.2.3 Global Anti-PD-1 Antibody Market Average Price (2021-2032)
- 2.3 Anti-PD-1 Antibody by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Monoclonal
- 2.3.3 Polyclonal
- 2.4 Anti-PD-1 Antibody by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 IHC-P
- 2.4.3 ICC/IF
- 2.4.4 ELISA
- 2.4.5 Flow Cytometry
- 2.4.6 WB
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-PD-1 Antibody Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-PD-1 Antibody Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Anti-PD-1 Antibody Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-PD-1 Antibody Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-PD-1 Antibody Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-PD-1 Antibody, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-PD-1 Antibody, Product Type & Application
- 3.8 Global Manufacturers of Anti-PD-1 Antibody, Established Date
- 3.9 Global Anti-PD-1 Antibody Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 3SBio Inc
- 4.1.1 3SBio Inc Company Information
- 4.1.2 3SBio Inc Business Overview
- 4.1.3 3SBio Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 3SBio Inc Anti-PD-1 Antibody Product Portfolio
- 4.1.5 3SBio Inc Recent Developments
- 4.2 Thermo Fisher
- 4.2.1 Thermo Fisher Company Information
- 4.2.2 Thermo Fisher Business Overview
- 4.2.3 Thermo Fisher Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Thermo Fisher Anti-PD-1 Antibody Product Portfolio
- 4.2.5 Thermo Fisher Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Anti-PD-1 Antibody Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Anti-PD-1 Antibody Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Lilly
- 4.5.1 Lilly Company Information
- 4.5.2 Lilly Business Overview
- 4.5.3 Lilly Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lilly Anti-PD-1 Antibody Product Portfolio
- 4.5.5 Lilly Recent Developments
- 4.6 Sino Biological Inc
- 4.6.1 Sino Biological Inc Company Information
- 4.6.2 Sino Biological Inc Business Overview
- 4.6.3 Sino Biological Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sino Biological Inc Anti-PD-1 Antibody Product Portfolio
- 4.6.5 Sino Biological Inc Recent Developments
- 4.7 Bristol-Myers Squibb (BMS)
- 4.7.1 Bristol-Myers Squibb (BMS) Company Information
- 4.7.2 Bristol-Myers Squibb (BMS) Business Overview
- 4.7.3 Bristol-Myers Squibb (BMS) Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bristol-Myers Squibb (BMS) Anti-PD-1 Antibody Product Portfolio
- 4.7.5 Bristol-Myers Squibb (BMS) Recent Developments
- 4.8 Abcam
- 4.8.1 Abcam Company Information
- 4.8.2 Abcam Business Overview
- 4.8.3 Abcam Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Abcam Anti-PD-1 Antibody Product Portfolio
- 4.8.5 Abcam Recent Developments
- 4.9 Abbvie
- 4.9.1 Abbvie Company Information
- 4.9.2 Abbvie Business Overview
- 4.9.3 Abbvie Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Abbvie Anti-PD-1 Antibody Product Portfolio
- 4.9.5 Abbvie Recent Developments
- 4.10 TG Therapeutics, Inc
- 4.10.1 TG Therapeutics, Inc Company Information
- 4.10.2 TG Therapeutics, Inc Business Overview
- 4.10.3 TG Therapeutics, Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 TG Therapeutics, Inc Anti-PD-1 Antibody Product Portfolio
- 4.10.5 TG Therapeutics, Inc Recent Developments
- 4.11 Ono Pharmaceutical Co., Ltd
- 4.11.1 Ono Pharmaceutical Co., Ltd Company Information
- 4.11.2 Ono Pharmaceutical Co., Ltd Business Overview
- 4.11.3 Ono Pharmaceutical Co., Ltd Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Ono Pharmaceutical Co., Ltd Anti-PD-1 Antibody Product Portfolio
- 4.11.5 Ono Pharmaceutical Co., Ltd Recent Developments
- 4.12 InvivoGen
- 4.12.1 InvivoGen Company Information
- 4.12.2 InvivoGen Business Overview
- 4.12.3 InvivoGen Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 InvivoGen Anti-PD-1 Antibody Product Portfolio
- 4.12.5 InvivoGen Recent Developments
- 4.13 Chugai Pharmaceutical Co., Ltd
- 4.13.1 Chugai Pharmaceutical Co., Ltd Company Information
- 4.13.2 Chugai Pharmaceutical Co., Ltd Business Overview
- 4.13.3 Chugai Pharmaceutical Co., Ltd Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Chugai Pharmaceutical Co., Ltd Anti-PD-1 Antibody Product Portfolio
- 4.13.5 Chugai Pharmaceutical Co., Ltd Recent Developments
- 4.14 BioVision Inc
- 4.14.1 BioVision Inc Company Information
- 4.14.2 BioVision Inc Business Overview
- 4.14.3 BioVision Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 BioVision Inc Anti-PD-1 Antibody Product Portfolio
- 4.14.5 BioVision Inc Recent Developments
- 4.15 Bio X Cell
- 4.15.1 Bio X Cell Company Information
- 4.15.2 Bio X Cell Business Overview
- 4.15.3 Bio X Cell Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Bio X Cell Anti-PD-1 Antibody Product Portfolio
- 4.15.5 Bio X Cell Recent Developments
- 4.16 BeiGene
- 4.16.1 BeiGene Company Information
- 4.16.2 BeiGene Business Overview
- 4.16.3 BeiGene Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 BeiGene Anti-PD-1 Antibody Product Portfolio
- 4.16.5 BeiGene Recent Developments
- 4.17 Arcus Biosciences
- 4.17.1 Arcus Biosciences Company Information
- 4.17.2 Arcus Biosciences Business Overview
- 4.17.3 Arcus Biosciences Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Arcus Biosciences Anti-PD-1 Antibody Product Portfolio
- 4.17.5 Arcus Biosciences Recent Developments
5 Global Anti-PD-1 Antibody Market Scenario by Region
- 5.1 Global Anti-PD-1 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-PD-1 Antibody Sales by Region: 2021-2032
- 5.2.1 Global Anti-PD-1 Antibody Sales by Region: 2021-2026
- 5.2.2 Global Anti-PD-1 Antibody Sales by Region: 2027-2032
- 5.3 Global Anti-PD-1 Antibody Revenue by Region: 2021-2032
- 5.3.1 Global Anti-PD-1 Antibody Revenue by Region: 2021-2026
- 5.3.2 Global Anti-PD-1 Antibody Revenue by Region: 2027-2032
- 5.4 North America Anti-PD-1 Antibody Market Facts & Figures by Country
- 5.4.1 North America Anti-PD-1 Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-PD-1 Antibody Sales by Country (2021-2032)
- 5.4.3 North America Anti-PD-1 Antibody Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-PD-1 Antibody Market Facts & Figures by Country
- 5.5.1 Europe Anti-PD-1 Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-PD-1 Antibody Sales by Country (2021-2032)
- 5.5.3 Europe Anti-PD-1 Antibody Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-PD-1 Antibody Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-PD-1 Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-PD-1 Antibody Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-PD-1 Antibody Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-PD-1 Antibody Market Facts & Figures by Country
- 5.7.1 South America Anti-PD-1 Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-PD-1 Antibody Sales by Country (2021-2032)
- 5.7.3 South America Anti-PD-1 Antibody Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-PD-1 Antibody Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-PD-1 Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-PD-1 Antibody Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-PD-1 Antibody Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-PD-1 Antibody Sales by Type (2021-2032)
- 6.1.1 Global Anti-PD-1 Antibody Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Anti-PD-1 Antibody Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-PD-1 Antibody Revenue by Type (2021-2032)
- 6.2.1 Global Anti-PD-1 Antibody Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-PD-1 Antibody Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-PD-1 Antibody Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-PD-1 Antibody Sales by Application (2021-2032)
- 7.1.1 Global Anti-PD-1 Antibody Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Anti-PD-1 Antibody Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-PD-1 Antibody Revenue by Application (2021-2032)
- 7.2.1 Global Anti-PD-1 Antibody Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-PD-1 Antibody Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-PD-1 Antibody Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-PD-1 Antibody Value Chain Analysis
- 8.1.1 Anti-PD-1 Antibody Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-PD-1 Antibody Production Mode & Process
- 8.2 Anti-PD-1 Antibody Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-PD-1 Antibody Distributors
- 8.2.3 Anti-PD-1 Antibody Customers
9 Global Anti-PD-1 Antibody Analyzing Market Dynamics
- 9.1 Anti-PD-1 Antibody Industry Trends
- 9.2 Anti-PD-1 Antibody Industry Drivers
- 9.3 Anti-PD-1 Antibody Industry Opportunities and Challenges
- 9.4 Anti-PD-1 Antibody Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst